ARTICLE | Company News
Merck sales and marketing update
February 16, 2015 8:00 AM UTC
Merck launched Belsomra suvorexant in the U.S. to treat adults with insomnia. The dual orexin receptor antagonist is available in 5, 10, 15 and 20 mg oral tablets with a wholesale acquisition cost (...